Michael Teitell, M.D., Ph.D.
James Heath, Ph.D.
Engineered devices and materials of 100 nanometers or less in size are showing potential in the detection, diagnosis, tracking and treatment of cancer. Approaches in nanotechnology applied to major problems in cancer are in their formative stages. The Cancer Nanotechnology Program brings together physicians and scientists from diverse disciplines in the physical and life sciences at UCLA and Caltech, in the common pursuit of improved understanding and outcomes in cancer.
- To provide a cross-disciplinary program that facilitates the development and application of nanotechnology approaches to basic and clinical problems in cancer
- Engineer, test and deliver a wide range of therapeutic anti-cancer nanoparticles
- Develop nanoscale imaging modalities to detect, quantify and track cancers
- Invent and refine custom surface, analytic and manipulative platforms using nanoscale engineering principles
- Translate promising approaches into preclinical model and early phase clinical testing
Meetings and Events:
- Quarterly program area scientific exchange dinners
- Invited speakers in the JCCC, IMED and CNSI seminar series
- Semi-annual, inter-programmatic symposia on Nanotechnology in Cancer
Dr. Michael Teitell is Director of the Cancer Nanotechnology Program and Director of the Division of Pediatric and Neonatal Pathology in the Department of Pathology and Laboratory Medicine at UCLA. He is a Scholar of the Leukemia and Lymphoma Society, a member of the American Society of Clinical Investigators, and a Stohlman Scholar. His collaborative research program co-invented a photothermal nanoblade, a pulse laser-assisted cell sorter and a live cell interferometer as new nanoscale approaches for genetic and biophysical manipulations, ultra high-speed cell sorting, and quantification of individual cancer and stem cells within large populations of cells in real-time.
Dr. James Heath is Co-Director of the Cancer Nanotechnology Program, the E.W. Gilloon Professor of Chemistry at Caltech, and Director of the NanoSystems Biology Cancer Center, a NCI Center for Cancer Nanotechnology Excellence (CCNE). His work has been recognized with the Feynman Prize in Nanotechnology, the Sackler Prize in Physical Sciences, the Doolittle Award, the Spiers Medal of the Royal Society, and he is one of the seven top innovators in the world according to Forbes. He leads a collaborative research program in cancer diagnostics using microfluidic devices, capture agents, single cell secretion systems, tumor hypoxia and protein regulation and dissection of cellular immunity against cancer by highly multiplexed approaches.